Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Beta Bionics, Inc.NASDAQ: BBNX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 62.4% from a year ago
Net receivables stood at $17.89M at the end of Q1 FY2026, up 62.4% from a year earlier and down 10.1% from the prior quarter.
Context
- Net receivables amounted to 5.9% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +62.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 19.89M USD
- Year-over-year change
- +65.8%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.89M | +65.8% |
| FY2024 | 2024-12-31 | 12M | +169.7% |
| FY2023 | 2023-12-31 | 4.45M | — |
| FY2022 | 2022-12-31 | 0 | — |
Net Receivables vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +62.4% is the highest of 6, against a peer median of +11.1%.
- Net receivables amounts to 5.9% of total assets for BBNX, versus a peer median of 16.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 108.51B DKK | +26.4% | +9.6% | 18.2% | |
| Jun 2026 | $1.28B USD | -6.8% | +19.7% | 19.9% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $782M USD | — | — | 16.6% |
| Jun 2026 | $588.7M USD | +32.4% | +36.0% | 18.6% | |
| Mar 2026 | $140.67M USD | +11.1% | +13.0% | 12.2% | |
| Mar 2026 | $28.74M USD | -0.6% | +31.7% | 3.9% | |
| Mar 2026 | $17.89M USD | +62.4% | — | 5.9% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BBNX) | — | +11.1% | +19.7% | 16.6% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.